Arbor Biotechnologies
Company Snapshot
Company Overview
Arbor Biotechnologies is an early-stage life sciences company based in Cambridge, Mass. Arbor was founded to curate genetic biodiversity and discover novel protein functions from nature by integrating proprietary high-throughput platforms with computational biology tools. Leveraging its innovative discovery platform, Arbor aims to transform the discovery of proteins to improve human health and sustainability.
Arbor’s discovery platform employs various technologies and techniques, including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, to curate and mine the natural genetic diversity for impactful peptides, proteins, and enzymes, enabling systematic and high-throughput discovery of new molecules.
Arbor was founded in 2016 by Feng Zhang of the Broad Institute at MIT, David Walt of the Wyss Institute at Harvard, and other founders. In June 2017, the company closed its $15.6 million Series A financing, led by Keith Crandell of ARCH Venture Partners, Annie Hazlehurst of Faridan Ventures and several private investors.
Utilizing its platform in March 2018, Arbor Biotechnologies published its first findings of a new member of the CRISPR-Cas13 enzyme family—Cas13d. The new enzyme is much smaller than other members of the CRISPR-Cas13 family and has implications for RNA manipulation and highly sensitive diagnostics applications.
Arbor Biotechnologies In Reports
Arbor Biotechnologies In News
Company's Business Segments
- Genetic Medicines : This segment focused on Discovering, Developing Potentially Curative Genomic Medicines.
Applications/End User Industries
- Biotechnology
- Bioengineering
- Discovery Science
- Molecular Biology
- DNA Sequencing
- Machine Learning
- DNA Synthesis
- Protein Biology
- CRISPR
- Gene Editing
- Life Sciences